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Abstract: 
Human islet amyloid polypeptide protein (hIAPP) is secreted by the pancreas along with insulin 
and is assumed to play a role in pathological development of type II diabetes. It has 37 amino 
acids in its sequence. Amyloid is formed due to misfolding of the protein, which is cytotoxic to 
beta cells in the pancreas of type II diabetic patients. The presence of amyloid deposits is also a 
characteristic feature of a number of other diseases like Alzheimer’s disease and Parkinson’s 
disease. Since insulin has been reported to interact with hIAPP and block amyloid formation, 
fragments of insulin were synthesized and the inhibitory effects were studied against an hIAPP 
analog in the presence of phospholipid vesicles. While these sequences might inhibit amyloid 
formation, preliminary results indicate that they actually enhance membrane damage, as 
measured by the increased leakage of carboxyfluoroscein dye from membrane model vesicles. 
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Chapter 1. Introduction                              
1.1 Background and Amino acids 
The field of biochemistry has been very diversified in the past decade or so, in order to 
understand the mysterious and new diseases that are coming at a very fast rate. To solve this 
problem we need to have a better understanding of the complex nature of human cells and their 
interactions with each other and exo-chemicals to which they are exposed.  This issue can only 
be solved by understanding the basic mechanism of every chemical reaction in the cells. 
To understand what is going on in the cells, we need to study the basic foundation of life, 
the amino acids. Amino acids are short carbon backboned molecules that have a carboxyl group 
at one end and an amino group at other end. The difference between each amino acids lies only 
by varying the side chain present on it, also called R groups. These R groups distinguish the 
amino acids from each other. The twenty amino acids each have unique characteristics, which 
depend on the length, structure, solubility, charge, and nature of the R groups. The structures of 
the amino acids are in Figure 1. 
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Figure 1. Twenty amino acids with neutral charge and abbreviated by three letters code.
1 
The twenty amino acids shown above undergo a process called a condensation reaction 
where the amino terminal of one alpha-amino acid reacts with the alpha-carboxyl terminal group 
of another amino acid, by losing a water molecule and forming an N-C=O bond, called an amide 
bond. Amino acids attached in this manner, if in a short chain of two to twenty amino acids, are 
called a peptide chain. If the peptide chain grows longer, then it is called a polypeptide. 
Polypeptides of high molecular weight perform certain biological functions and are called 
proteins. A protein is usually a very long linkage of amino acids, from dozens to several 
3 
 
thousands. Its pattern and structural integrity are very important for its biological function. 
Theories have suggested that even minor changes of less than one percent can cause huge 
fluctuations in their biological activity and function. 
 
1.2 Protein Structure: 
  When proteins are explored using a technique called crystallography, their three 
dimensional structures are revealed, and these structures are classified into four levels: primary, 
secondary, tertiary, and quaternary (Figure 2). Primary structures of a protein are simple 
sequences that are linearly arranged in space, forming the backbone. Secondary structure is 
where the backbone is twisted spatially, forming helical or pleated segments. Tertiary structure is 
the compact structure of any protein including backbone and side chain arrangements, and in this 
form it’s functional (function of the protein is associated with tertiary structure). Quaternary 
structure occurs in some of the proteins that consist of two or more polypeptide units. Each and 
every protein and polypeptide have a unique and specific three-dimensional structure associated 
with them. This uniqueness comes from the arrangement of amino acids in their peptide chain. 
Their conformation allows them to express their functions and activity. Moreover, many proteins 
have an inhibition or activation region where it is sterically hindered, allowing only specific bio-
molecules or foreign molecules to interact and bind to this region. 
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Figure 2. Schematic representation of protein structure
2
. 
If proteins adopt their regular conformation, they can perform normal physiological 
functions. But if there is any mis-folding in the protein, then the protein generally becomes 
insoluble and forms aggregates and damages the cells around them to causes diseases. One of the 
proteins that is implicated in the development of disease is known as amylin or human islet 
amyloid polypeptide. 
1.3 Diabetes 
The term diabetes is defined as a disease state associated with elevated blood sugar levels 
due to improper use of blood glucose. As we ingest food, it needs to be assimilated, processed, 
5 
 
and digested in our body with the help of a hormone called insulin. Insulin is secreted from the 
pancreas, in the islets of Langerhans. Diabetes is of two types
2
: Type I diabetes and Type II 
diabetes. 
Type I diabetes is diagnosed generally in people aged less than 15 years and is believed 
to be due to hereditary causes, the passage of genes from one generation to another. This type 
contributes only ten percent of the world diabetes population. 
Type II diabetes is generally observed in older people, usually above 45 years, and is 
caused by a metabolic disorder. Type II diabetes is also called non-insulin dependent diabetes 
mellitus (NIDDM). Type II diabetes affects roughly 150 million people around the globe
3
 and is 
a chronic and progressive disease. Type II diabetes usually is associated with obesity, high blood 
pressure, and hypercholesterolemia. This type contributes about ninety percent of the world 
diabetes population, so immediate attention is required to help the people suffering from this 
dangerous disease. 
1.4 IAPP 
Islet Amyloid Polypeptide, also known as amylin, is of particular importance in Type II 
diabetes because of the way it mis-folds, causing amyloid fibril formation, which, in turn, can 
cause many diseases.  The pathology of Type II diabetes (T2DM) is the cytotoxic deposits of 
amyloid fibrils in the islets of Langerhans, and the main component of these deposits is the Islet 
Amyloid Polypeptide (IAPP)
 4
.  Eighteen percent of Americans over the age of 60 develop Type 
II diabetes, and the estimated cost for the treatment of diabetes is around $132 billion, which is 
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10% of geriatric health care costs
3
. As the population gets older, the impact of this disease is 
expected to grow dramatically, making the study of this disease even more important. 
 
1.5 hIAPP 
Human IAPP (hIAPP) or amylin is a 37-residue polypeptide that is co-secreted along 
with insulin from pancreatic β-cells. Amylin protein is generally involved in appetite 
suppression. In 1900, the appearance of IAPP in the islets of Langerhans by hyalinization was 
first noted by Eugene Opie in diabetic patients.  This protein is thought to behave as a hormone 
in normal individuals, and this was shown by Cooper et al in 1988.
5
  
Later Friedrich and Kekule demonstrated the presence of amylin protein in amyloid 
masses, and today amyloid refers to fibrillar structures that are found to be a major component of 
Alzheimer’s disease, Prion disease, Type II diabetes mellitus and Parkinson’s disease. This 
misfolded protein is closely related to disease progression and is also found to contribute to cell 
death.
6
   
The aggregates of misfolded islet amyloid polypeptide found in Type II diabetes patients 
are composed of β sheet amyloid fibers. Such amyloid deposits have been found in the pancreas 
of more than 90% of diabetic patients upon autopsy. When amino acid sequences of unrelated 
amyloid forming proteins are compared, it is seen that aromatic residues are conserved among 
these proteins.
7,8
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1.5 .1 hIAPP Functions: 
hIAPP is also called amylin, IAPP or DAP (diabetes associated protein).
5
  Its synthesis 
and secretion have been well studied but in contrast, the exact physiological function of the 
polypeptide remains unclear. Some of the functions of hIAPP are suppression of insulin-
mediated glucose uptake in skeletal muscle and inhibition of glucose-stimulated insulin secretion 
(Swiss Prot Id P10997).
9
  It also suppresses glucagon release from isolated islets
10
 and regulates 
food intake and controls body weight.
10
 The peptide also regulates renal filtration, with IAPP 
binding sites which are localized to the kidney, in addition to calcium homeostasis and 
vasodilation. 
1.5.2 hIAPP Gene structure and location 
The total size of gene hIAPP is 6599 base pairs (Entrez gene id: 3375).  The precursor 
protein contains 89 amino acids (Refseq: NP_000406).  Its mRNA is 1462 base pairs long and 
contain 3 exons (NM_000415).  It is located on chromosome 12 (NC_000012.10) of the human 
genome, gene locus is 12p12.3-p12.1. 
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The ensemble data base shows the protein and its components clearly in Figures 3 and 4.
11 
 
 
Figure 3. Scale (aa) shows total length of the protein, here different parts of the protein are 
clearly distinguished.  There are two snp (single nucleotide polymorphism) sites at the 53
rd 
(SNP 
ID: rs 1800203)
12
 and 75
th
 positions (SNP ID: rs11558904).
12
 The average residual weight of the 
protein is 110.184, the charge of the peptide is 7.5, and isoelectric point is at pH of 
10.3921(Ensembl peptide id is ENSP00000240652).
12
 
 
 
Figure 4. Location of hIAPP in humans according to gene cards
13 
on chromosome12. 
 
The structure of hIAPP is closely related to calcitonin gene-related peptide, CGRP (PF00214).
14
  
“Two cysteine residuals are conserved from the N-terminal of these peptides and are known to 
be involved in a disulphide bond.”14 (Figure 5). 
9 
 
 
       xCxxxxxCxxxxxxxxxxxxxxxxxxxxxxxxxxxx-NH(2) 
          |            |                             Amide group 
          +--------+ 
 
'C': conserved cysteine involved in a disulphide bond. 
 
Figure 5. Two cysteine residues are involved in disulphide bonding.
14 
1.5.3 Role of hIAPP in Type II diabetes  
Although definite functions have yet to be clearly ascribed to IAPP, its fundamental 
pathogenic role is the formation of the islet amyloid in the pancreas of individuals with Type II 
diabetes.  hIAPP plays an important role along with insulin in healthy individuals to maintain 
glucose homeostasis.
15
 In beta cells of the pancreas, hIAPP is present in very small quantities, 
roughly about one percent when compared to that of insulin in the beta cells. Because it is 
present in lower quantities, the clearance rate is also low. This makes the hIAPP highly 
concentrated during the fasting state when compared to insulin, at 10-15% of insulin levels.
16
  
As mentioned previously, hIAPP is implicated as the main component in amyloid fibril 
deposits, which have been found by post-mortem examination in more than 95% of Type II 
diabetic patients. There seems to be a natural mechanism whereby these fibrils of hIAPP are not 
found in healthy individuals, where hIAPP is soluble and functional.  
When hIAPP forms fibrils, they are dense, insoluble, and long beta sheet structures. 
These fibrils allow the entry of calcium ions into the pancreatic beta cells, due to the formation 
of small pores or holes, or complete disruption of the membrane. Due to this membrane 
10 
 
disruption, integrity of the cell is lost, thereby creating extra work for mitochondria to maintain 
the ion-balance, and this extra pressure leads to oxidative stress and eventually cell death 
(apoptosis). A lot of research still needs to be done to determine whether cells develop pores or 
the membrane is completely disrupted; it’s still a million dollar question to the scientists working 
in the field of membrane disruption and hIAPP. 
Figure 6 illustrates some of the possible mechanisms that researchers believe may lead to 
membrane disruption. The method that causes disruption is dependent on the environmental 
conditions. At low concentrations in solution, peptides are seen as monomers as shown in Figure 
6. As the concentration of peptide is increased, monomers start to self-assemble.
17
 As the 
concentrations are increased even further, three mechanisms are possible: barrel-stave, detergent 
like, and torodial-wormhole. Each of these three mechanisms is completely different in how it 
causes membrane disruption. In the barrel-stave model, peptides form transmembrane pores by 
aggregating. In the detergent model, the membranes are pulled apart leading to complete 
disruption. In the torodial-wormhole model, both the lipids and peptides act as a membrane 
lining, and this lining is destabilized, creating a curvature strain.
18
 
 
 
 
 
 
11 
 
 
 
Figure 6. Six different states of how peptides are involved in membrane disruption.
17
 
A: Peptides in solution, usually unstructured. B: Peptide acts as monomer. C: Peptides 
self assembled on a surface. D: Barrel-stave model. E: Torodial wormhole model. F: 
Detergent model. 
 
Interestingly, the mature fibrils of hIAPP in solution are not cytotoxic to beta cells, 
implying that development of the Type II disease is not solely caused by the physical appearance 
12 
 
of fibrils but that the fibril forming process may be cytotoxic.
19
 hIAPP fibrilization occurs in 
vitro at almost 100 fold less concentration than that in vivo within beta cells where both hIAPP 
and insulin are stored. A reasonable explanation for this would be that stabilizing agents are 
present in vivo, which help the hIAPP not to form fibrils.
20
 Insulin has been proven to inhibit 
fibril formation in vitro.
21 
Fibril formation of hIAPP in the absence and presence of insulin has 
been monitored and sub-stoichiometric amounts of insulin increase the conversion time to fibers 
by eight-fold.  In addition, the half time for conversion increases in a linear fashion with insulin 
concentration.
4
  
After many years of research with insulin and hIAPP, the recognition sequence between 
them was identified in the year 2006.
20
 It was shown that the B-chain of insulin inhibits the 
intermediately formed coiled of hIAPP, which eventually forms a fibril forming beta-sheet 
conformation. Based on the results obtained from previous studies, several decapeptides based 
on insulin were synthesized and tested for interaction with hIAPP, and the domain corresponding 
to 10-19 (HLVEALYLVC) was found to bind strongly to hIAPP. This region is thought to 
interact with hIAPP 10-19 (QRRANFLVHS).  It was proposed that this region was the 
recognition interface of hIAPP and insulin. In addition to this, there are some homologous 
regions in both hIAPP (ANFLV) 13-17, and insulin (ALYLV) 14-18, which may represent core 
recognition sites between the two sequences, which can prevent fibril formation. In fact, 
interestingly the aromatic tyrosine found in the center of the insulin sequence aligns exactly at 
the aromatic phenylalanine of the hIAPP sequence, making it possible for π interactions that may 
disrupt those between hIAPP molecules at the beginning stages of amyloid formation.
8
 In this 
project, the recognition site of the native inhibitor insulin was employed in designing smaller 
peptides in an attempt to prevent or slow down the process of fibril formation and membrane 
13 
 
damage in model liposomes. As previously stated, insulin is a natural inhibitor of hIAPP 
aggregation and fibril formation. The peptide analogs were designed based on the insulin 
sequence reported to make contact with hIAPP. The initial sequence HLVEALYLVC was then 
truncated one amino acid at a time to determine the shortest insulin sequence that prevents fibril 
formation. The shorter sequence was designed with the aim of making it economically 
advantageous and easy to synthesize and may also serve as a basis for peptidomimetic drug 
inhibitors to cure fibril formation and the cytotoxity of hIAPP.   
1.6 Peptide synthesis overview 
There are several types of peptide synthesis available, but the most convenient and 
effective small scale production of peptides for research labs is solid phase peptide synthesis. 
Solid phase peptide synthesis (SPPS) was introduced by Merrifield.
22, 23
 In solid phase peptide 
synthesis, one can easily control the peptide length as well as modify the peptide by adding any 
desired unnatural or D-amino acids. The important mechanism behind this process is repeated 
coupling and deprotection of amino acids at each and every step by various solvents. Once the 
solid support resin is placed in the reaction vessel, it is deprotected and the C-terminal amino 
acid (with amine protection) is added to attach to it. Then the N-terminus of the peptide is 
deprotected to allow the next coupling to occur. This process is repeated and the peptide can be 
obtained with ease, since it stays attached to the solid support while soluble impurities are 
washed away at each step. If done properly, a yield of more than 90% can be achieved. A 
scheme is in Figure 7.
24
 
There are two types of solid phase synthesis available. One is Fmoc and the other is tBoc. 
These are classified on the basis of the amine protecting groups at the end of the amino acids 
14 
 
where further addition takes place. Fmoc, Fluorenyl-methoxy-carbonyl, is the advanced and 
widely used protectant group on solid phase peptide synthesis. The tBoc method was the first to 
be used but is less utilized today due to the requirement to use dangerous hydrofluoric acid to 
remove the peptide from the resin. In the Fmoc method to remove the protective group, 20% 
piperdine in DMF is regularly used. Last, the peptide is cleaved from the resin using 
trifluoroacetic acid. 
 
 
 
 
 
 
 
15 
 
 
Figure 7. Schematic diagram of solid phase peptide synthesis.
24
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1.7 Dye Leakage Studies 
Dye leakage studies are the best technique to study membrane damage models. Dye leakage 
assay studies use the property of fluorescence to determine the leakage caused by IAPP of 
encapsulated dye from lipid membranes. The fluorescence studies use a dye called 
carboxyfluorescein. First the lipid vesicles are created, allowing incorporation of 
carboxyfluorescein dye into the vesicles. When the membrane gets damaged, the dye is released 
into the media. The concentration of the leaked dye can be measured using a scanning 
spectrofluorometer. This can be correlated to the extent of membrane damage. Later, the percent 
of dye leaked can be plotted against time to determine time dependent effects. 
The lipid membranes which are commonly used in dye leakage studies are 
Palmitoylolenylphospoglycerol (POPG), 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) and 1,2-dioleoyl-sn-glycero-3-(phospho-L-serine) (DOPS).  The structures and 
relative charges of POPG, DOPC and DOPS are shown in Figure 8.
26, 27, 28
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Figure 8. Structural representations of lipids POPG, DOPS and DOPC.
25, 26, 27
 
 
 
 
 
 
Structure of POPG, a negatively charged lipid 
Structure of DOPS, a negatively charged lipid 
Structure of DOPC, a neutral lipid (zwitter 
ionic) 
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CHAPTER 2  
Research goals and objectives 
2.1 Hypothesis 
 The main goal of this project was to synthesize varying length insulin-based inhibitors of 
hIAPP to prevent aggregation and eventually prevent cell death. Two peptides of length 9 and 10 
amino acids were synthesized using solid peptide synthesis, and their action was observed in the 
presence of models resembling lipid membranes. The main focus of this study was to truncate a 
sequence of insulin that was known to make contact with hIAPP and see its action in preventing 
the aggregation process. In order to see its effects, first two different peptides were synthesized, 
LVEALYLVC and HLVEALYLVC, which were purified and confirmed with analytical HPLC 
and LC-MS. Then the activity of the peptides was tested in the presence of hIAPP 1-19 (the N-
terminal region also known to cause damage) and hIAPP 1-37 in model membranes. 
Initially we started testing insulin analog inhibitors in the presence of hIAPP 1-19 and 
hIAPP 1-37 in POPG. Later, based upon other studies, we confirmed the best mimicking 
membrane models were DOPC: DOPS in a 7:3 ratio. Then we continued performing experiments 
with the vesicles that best mimic the pancreatic cells in humans. 
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CHAPTER 3 
 
Experimental Procedures 
 
3.1 Peptide Synthesis 
  The insulin analog inhibitors LVEALYLVC and HLVEALYLVC were synthesized 
using standardized Fmoc methods using a Ranin PS3 peptide synthesizer on a 0.1 mmol scale 
basis. The required amino acids essential for the synthesis of peptides were weighed (0.4 mmoles 
each) in a vial. All vials consisted of a 1: 1 ratio of amino acid and coupling agent, HBTU 
(Hydroxy-O-(Benzotriazol-1yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate). The amino 
acid vials were arranged in sequence from C-terminus to N-terminus on the synthesizer. 0.4 M 
N, N- diisopropylethylamine in dimethylformamide (DMF) was used as the activator in peptide 
synthesis. The synthesis of peptides was done using a single coupling program. The solvent was 
N, N-dimethylformamide, and a 20% piperidine solution was used for deprotection. All of the 
amino acids used in the research project were bought from Midwest Biotech Inc. or Protein 
Technologies Inc., while solvents and other chemicals were purchased from Fischer Scientific. 
All of the amino acids, solvents, and chemicals were at least ACS standard grade. 
3.2 Peptide Cleavage 
After the peptide synthesis, the peptide bound to resin was transferred to a coarse fritted 
glass funnel with the help of methylene chloride and DMF. The resin in the coarse fritted glass 
funnel was washed with DMF, ethanol, and methylene chloride and dried under vacuum for 30 
minutes to one hour. Then the peptide bound resin was transferred to a 50-ml beaker with a 
20 
 
stirring bar and placed in an ice bath. The cleavage cocktail was added, which contained 0.5 ml 
anisole, 10 ml TFA, 1 crystal of phenol, and 0.5 ml water. The reaction was stirred for two hours 
at room temperature. This enabled the resin to separate from the peptide, after which the peptide 
can be found in a dissolved state, whereas the resin is found in an insoluble state (remains as 
solid). 
The resin was separated from the peptide through a filtration step, using a coarse fritted 
glass funnel. The filtrate was collected using a side arm flask, and repeated washing with TFA 
enabled the collection of all of the peptide through a filtration process. To the filtrate collected, 
60 mL of cold diethyl ether was then added while stirring slowly, which precipitated the peptide 
from solution so that it could be separated and collected through filtration through a fine fritted 
glass funnel. This solid was vacuum dried for 30-45 minutes, and then it was transferred to a 
lyophilization flask containing 70% acetonitrile in water. An equal amount of distilled water was 
added and the flask and contents were frozen. The peptide was kept on a lyophilizer under 
vacuum overnight to remove any liquid, leaving behind solid peptide. 
3.3 Peptide Purification and Analysis 
 Once the lyophilization was done, the peptide obtained was weighed on an analytical 
balance, and then the peptide was dissolved in the minimum amount of DMF and injected on to 
the reverse phase high performance liquid chromatography (RP-HPLC) column. The HPLC used 
was purchased from Waters, Inc. The absorbance used depended upon the type of amino acids 
present in the peptides. If the peptide contains phenylalanine the characteristic absorbance is seen 
at 254 nm, and peptides containing tyrosine have a characteristic absorbance at 280 nm. Both of 
the peptides used in this project contained tyrosine, so 280 nm was used. The solutions used for 
21 
 
the mobile phase were 0.1% trifluoroacetic acid (TFA) in water (solvent A) and 0.1% TFA in 
acetonitrile (ACN, solvent B). Initially to equilibrate the column, the mobile phase solvents were 
run for 20 minutes with 90% solvent A and 10% solvent B.  For separation, a gradient was 
selected with a flow rate of 10 ml /min, changing the composition of the mobile phase to 50% 
solvent B over the time period of two hours. Depending upon the absorbance of the peaks, the 
elutant was manually separated in test tubes. Typically the larger peak was the desired peptide. 
The collected solutions of pure peptide were combined, frozen, and lyophilized overnight.  
After the purification, the desired peptide identity and purity were confirmed in two 
ways. One was running the peptide solution through an analytical column by HPLC, and the 
other was confirming its mass by liquid chromatography combined with electrospray mass 
spectrometry (LC-MS). Using the first method, RP-HPLC, the peptide solution that was 
previously purified was run on the analytical column to make sure no other contaminants were 
present. The peptide purity was calculated by integration of peak areas using analytical RP-
HPLC on a Waters dual pump system that consisted of a gradient controller and UV detector. 
The column used was a Phenomenex Jupiter column. The mobile phase used was solvent A (0.1 
% TFA in water) and solvent B (0.1 % TFA in acetonitrile). Initially the pumps were run on 
isocratic to equilibrate the column at 1 mL/min with 100% solvent A. Then a gradient was 
designed at the same flow rate but changing the composition of solvent B over 30 minutes from 
0 to 66 percent. Once the column was equilibrated, a tiny amount of pure peptide was dissolved 
in a small amount of DMF and injected. There should be only one major peak, which confirms 
that the peptide is pure, or the previous purification step must to be done again. In this case, the 
target peptides were found to be greater than 99 percent pure, and their respective molecular 
weights were 1022.28 (LVEALYLVC) and 1159.42 (HLVEALYLVC). The pure peptide was 
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then weighed, labeled, and stored in the refrigerator until the dye leakage assays were ready to be 
commenced. Table 1 below shows the description and details of both the preparative and 
analytical HPLC and the columns used in the research project. 
Table 1. Specifications of HPLC used in the project 
Name and Function Specifications 
Preparative HPLC Water 600S controller 
Waters 616 pump 
Water 484 tunable Abs. detector 
Fisher Recordall Series 5000 
Preparative column Phenomenex Jupiter 
10µm, C18 250 * 21.2 mm and 300 A
0
 
Analytical HPLC Waters automated gradient controller 
Waters 515 HPLC pump 
Waters 490 E programmable multi-wavelength detector 
Shimadzu CR901 chromatopac integrator 
Analytical column Phenomenex Jupiter 
5µm, C18, 250 *4.6mm and 300 A
0
 
  
3.4 Dye leakage assay experiments 
The main principle used in this experiment was fluorescence, and the fluorescent dye 
carboxyfluorescein was used. When this dye escapes or leaks from the vesicles due to membrane 
damage caused by hIAPP, the fluorescence measured is proportional to the amount of dye 
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released. For this experiment we used two different types of lipids: 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-(phospho-L-serine) (DOPS). 
3.4.1 Vesicle creation 
For the type of vesicles being created, 5mg total of DOPC and DOPS in a 7:3 ratio were 
weighed in a test tube and dissolved in 2 mL of chloroform. Excess chloroform was blown off 
with nitrogen after the lipid was dissolved. Once the excess chloroform was blown off, it left a 
thin film of lipid behind, which was dried under vacuum by lyophilizer overnight. Then the dye 
was encapsulated in the lipids by dissolving 5.64 mg of carboxyfluorescein in 0.5 mL of sodium 
phosphate buffer at pH 7.5. Once the dye solution was ready, 0.5 mL was taken and added to the 
dried lipid test tube, which was then vortexed and subjected to freeze-thaw cycles five times 
using liquid nitrogen or dry ice/acetone. This enabled the dye encapsulation inside the lipid 
vesicles as they formed. The test tubes were labeled and stored at -20
o
C for later use. 
When it was time for the assay, the dye encapsulated lipid test tubes were removed from 
the freezer and thawed, and the extruder was assembled. Then the lipid solution was passed 
through the extruder 21 times. The extruder was purchased from Avanti Polar Lipids and 
consisted of seven pieces, including two plastic syringe insert pieces, a plastic washer, two 
exterior steel pieces, and two rubber o-rings that fit into groves of the plastic insert pieces. Glass 
syringes were inserted here. In between the two exterior steel pieces was placed a 0.1 micron 
polycarbonate membrane and two filter supports, which were immersed in buffer before 
carefully placing them between the syringe insert pieces. The extrusion was done by passing the 
solution through the poly-carbon membrane 21 times, which required some pressure. This made 
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the vesicles the desired size and uniform throughout the solution. Once the extrusion was 
complete, it was time to dissemble the extruder and save the vesicle solution in a test tube. 
The vesicle solution was placed on the top of a gel exclusion column with a Pasteur 
pipette, and allowed to run through the gel bed. This technique separates small dye molecules 
from the large vesicles. The large vesicles reach the bottom first since they are excluded from the 
gel pores, and the smaller molecules move more slowly. As the vesicles passed through the 
column, different color bands started to appear. The first yellow-colored fraction that came off 
the column was collected in a microvial. Then the column was flushed with buffer. The gel used 
was Sephadex G-50 from Sigma. In a similar fashion, vesicles without dye were also prepared, 
created in the same way but without carboxyfluorescein. The same steps of extrusion were done, 
but the gel exclusion was not necessary since there was no free dye to separate from the vesicles. 
3.4.2 Preparation of detergent, control, and peptide solutions  
For the preparation of the detergent solution, Triton X 100 detergent was used. 40µL of 
detergent was added to 250µL of sodium phosphate buffer at pH 7.5. This detergent causes 
damage to all of the lipid membranes prepared, leading to 100% of the dye leaking from the 
vesicles. This provides a positive control (100% leakage) when 50µL of this solution and 20µL 
vesicle solution were added to 1430µL buffer. 
The control solution was prepared by dissolving 50µL of DMSO and 20µL of lipid 
vesicles in 1430µL of sodium phosphate buffer. The control will not cause any damage to the 
lipid membranes, causing 0% leakage. The control solution does not contain detergent or peptide 
to cause damage to lipid membranes. 
25 
 
Preparation of peptide solutions: Both amylin and insulin fragment stock solutions were 
prepared to 0.72 M concentrations of peptides. Both insulin and amylin analogs were weighed 
and dissolved in DMSO to make the concentration 0.72M. 
For amylin samples, 1.0 mg of amylin (molecular weight =3905 g/mol) was weighed and 
dissolved in 385µL of DMSO, giving the 0.72M stock solution. 
For insulin samples, 3.0 mg of insulin (molecular weight = 5808 g/mol) was weighed and 
dissolved in 715µL of DMSO in a vial, giving a 0.72 M stock solution. Based on their individual 
molecular weights, insulin analogs were weighed out and dissolved in the required amount of 
DMSO, usually 375µL of DMSO, which gave rise to the final concentrations of 0.72 M. For 
LVEALYVC (MW 1022.28), 0.28mg was dissolved in 375µL DMSO. For HLVEALYVC (MW 
1159.42), 0.31mg was dissolved in 375µL DMSO. In order to test the effects of insulin and 
amylin themselves, the samples vials were made up as shown in Table 2. 
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Table 2. Sample tubes of Amylin/Insulin in varying volumes 
Tube Amylin/Insulin 
       (µL) 
Lipid 
vesicles 
     (µL) 
Buffer ( sodium 
phosphate pH 7.5) 
     (µL) 
Concentrations of 
Amylin/Insulin (µM) 
1 1 20 1479 0.5 
2 2.5 20 1477.5 1.2 
3 5 20 1475 2.4 
4 10 20 1470 4.8 
5 12.5 20 1467.5 6 
6 25 20 1455 12 
7 37.5 20 1442.5 18 
8 50 20 1430 24 
 
To study the effects of variable amounts of the synthesized insulin analogs with a constant 
concentration of amylin (2.4 µM), the sample tubes were made up as presented in Table 3. 
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 Table 3. Samples of constant amylin plus varying concentrations of synthesized insulin analog 
inhibitors in varying volume 
Tube Amylin 
(µL) 
 
Insulin 
Analog 
 
(µL) 
Lipid 
Vesicles 
(µL) 
 
Insulin Analog 
Conc. 
(µM) 
Buffer 
(µL) 
Ratio of insulin 
analog/amylin 
0 5 0 20 0 1475 N/A 
1 5 1 20 0.5 1474 1:5 
2 5 2.5 20 1.2 1472.5 1:2 
3 5 5 20 2.4 1470 1:1 
4 5 10 20 4.8 1465 2:1 
5 5 12.5 20 6 1462.5 2.5:1 
6 5 25 20 12 1450 5:1 
7 5 37.5 20 18 1437.5 7.5:1 
8 5 50 20 24 1425 10:1 
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3.5 Measurements of fluorescence values using Flx 800 microplate reader 
All of the test tubes containing buffer, peptides, and vesicles were mixed well, and 300 
µL of each solution from the test tubes was transferred to a 96 well plate. Tips were changed for 
each sample. All of the trials were performed in triplicate, and average values were calculated. 
A Biotek FLx Fluorimeter was used for this study.  The excitation and emission 
wavelengths for the instrument were 485 nm and 528 nm, respectively. When samples were 
transferred and ready to go, the instrument lid was closed; then the instrument measured the 
fluorescence values depending upon the dye leaked through the vesicles. All assays in this study 
were run for three hours, and the interval time for reading was 59 seconds. The formula used to 
calculate fraction of dye leakage from the lipid membrane was: 
Percent Fraction Leaked = [(Value-Control)/(Detergent-Control)] *100 
Finally, the percent leakage versus time was plotted for each concentration of each peptide and 
compared against each other. Higher percent leakage implies higher damage to the membrane. 
From the graphs plotted, time dependence effects could also be observed. 
 
 
 
 
 
29 
 
4. RESULTS AND DISCUSSION 
 Using the solid phase peptide synthesis technique, two analogs of insulin were 
synthesized, LVEALYLVC and HLVEALYLYC. These two insulin analog inhibitors were 
designed to interact with hIAPP and prevent the aggregation process, thereby protecting the 
membranes from damage.  
Dye leakage studies were done to see the activity of these inhibitors in different lipid 
membranes that mimic pancreatic cells. In this dye leakage assay, the lipid vesicles are treated 
with peptides (insulin analog inhibitors and hIAPP). The dye escapes or leaks from the vesicles, 
which enables the monitoring of fluorescence. Percent fluorescence is directly proportional to the 
amount of membrane damage in a given amount of time. These results indicate the extent of 
damage to the lipid membranes caused by the hIAPP in the absence and presence of synthesized 
peptides. All of these dye leakage studies were run for 3 hours in triplicate, and average values 
were taken to plot the graphs. It should be noted that the results obtained from each individual 
dye leakage assay may not be comparable to other assays, due to variability in conditions such as 
temperature and vesicle preparation quality, and unavoidable experimental errors.  Results are 
considered valid within individual trials, however, since each trial has its own control tubes. 
 The lipid model membranes used to mimic the somatic body cells are 7:3 DOPC/DOPS. 
This ratio and lipids are commonly used in liposome models of membrane systems. DOPC is 
zwitterionic, and DOPS is a negatively charged lipid. This ratio with 30% negatively charged 
lipid membrane serves as the best model for pancreatic beta cells to study membrane disruption. 
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Figure 9. Percent membrane disruption of varying concentrations of hIAPP over time in 7:3 
DOPC: DOPS. 
From the dye leakage assay studies, the interaction between the pancreatic beta cell- 
mimicking model membranes and twelve concentrations of hIAPP are displayed in Figure 9. The 
fluorescence values were collected every minute for three hours. The graphs were made by using 
the formula described earlier, plotted against time for each concentration. From Figure 9 it can 
be seen that membrane leakage increased over time, implying time dependence and the 
possibility of aggregate formation. Concentration-dependent damage can also be seen. As the 
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concentration is increased, the damage increases proportionally, and the highest concentration 
tested, 50µM, yielded 100% leakage after 3 hours. 
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Figure 10. Average values of percent dye leakage against varying concentration of hIAPP in 7:3 
DOPC/DOPS. 
  In order to show the concentration dependent damage of hIAPP, the average values were 
taken at each time point and plotted against concentration values of hIAPP. In Figure 10, the 
time-averaged percent membrane disruption was plotted against varying concentrations of 
hIAPP, and a clear concentration dependent damage can be seen. In this graph, 50µM hIAPP 
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produce over 80% membrane damage. A logarithm regression was also done on the graph with a 
correlation coefficient of 0.87. 
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Figure 11. Percent membrane disruption observed with 10µM constant concentration of hIAPP 
and varying concentrations of insulin. 
 In order to observe both increases and decreases in membrane damage brought about by 
insulin, an optimal concentration of hIAPP was selected. A 10µM concentration of hIAPP was 
used and twelve varying concentrations of insulin, from 0µM to 100µM, were run against the 
constant hIAPP. Figure 11 shows a mixed effect of insulin with no clear evidence of 
concentration dependence. However, it is clear that hIAPP at 10µM concentration without 
insulin showed much more damage as the time increased. Addition of insulin does appear to 
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reduce membrane damage over time, implying a possible role in slowing the fiber formation. 
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Figure 12. Average values of percent dye leakage for constant 10µM concentration of hIAPP 
against varying ratios of insulin to hIAPP. 
 The graph in Figure 12 was obtained by taking the average percent membrane disruption 
over time versus the ratio of insulin to hIAPP. It can be seen from the graph that membrane 
disruption is generally higher without insulin, confirming a possible role of insulin in preventing 
membrane damage. At a 0.2:1 ratio of (insulin)/ (hIAPP) there is a sharp decrease in the percent 
membrane damage, indicating a 13% reduction. Beyond this ratio of (insulin)/ (hIAPP), the 
membrane damage reduction is variable and less notable. One hypothesis for this observation is 
that hIAPP forms a five-subunit complex and binds to one subunit of insulin forming a six-unit 
complex (hexamer). This hexamer may not interact with membranes as the monomers do. This 
optimal ratio of 0.2:1 (insulin)/ (hIAPP) was seen in many trials and is interesting because 
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insulin is stored in secretory granules of the pancreas as a hexamer. Still, the reduction in 
membrane damage observed was minimal at 13%. 
 Figure 13 shows the effect of varying concentrations of the first inhibitor, 
HLVEALYLVC, in 7:3 DOPC/DOPS in the presence of 10µM hIAPP.  
 
  
Figure 13. Percent membrane disruption of HLVEALYLVC against 10µM hIAPP 1-37. 
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The percent membrane disruption caused by hIAPP in the presence of HLVEALYLVC 
was observed by keeping the hIAPP concentration constant at 10µM. The insulin analog 
concentration was varied from 0µM to 101.7µM. As shown in Figure 13, as the concentration of 
analog is increased, the percent membrane disruption also increases significantly. Even at low 
concentrations, the insulin analog is apparently aiding in causing damage to the lipid mimicking 
membrane models. As the concentration is increased to 10µM inhibitor, the percent membrane 
disruption levels goes to about 80%. After that point, the damage levels off. This significant 
increase in membrane damage may be caused by the analog interacting with the hIAPP. Since 
the only difference in sequence between this analog and the other one (which showed a different 
effect, as will be discussed below) was the histidine at the N-terminus, it is also possible that the 
partial positive charge of this side chain gives the analog the ability to interact with the 
membrane directly rather than with hIAPP, making their effect additive. 
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Figure 14. Ratio of insulin analog HLVEALYLVC to hIAPP versus percent membrane 
disruption. 
 Figure 14 shows time averaged disruption versus the ratio of inhibitor to hIAPP. It is 
clear from the graph that the insulin analog is not preventing membrane disruption at any ratio 
and is in fact contributing somehow to the membrane damage. However, once the 1:1 ratio is 
reached, damage is maximized and further increases in peptide have no significant effect. 
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 Figure 15. Percent of dye leakage from model 7:3 DOPC/DOPS liposomes in the presence of 
10µM hIAPP and varying concentrations of LVEALYLVC over time. 
 In Figure 15, we can see the effect of insulin analog LVEALYLVC, keeping the hIAPP 
concentration constant at 10µM and running the assay over 180 minutes. The insulin analog 
concentrations ranged from 0µM to 100µM. From the graph the insulin analog LVEALYLVC is 
protecting the membrane from disruption caused by hIAPP at lower concentration; the 
membrane disruption is reduced at LVEALYLVC concentrations lower than 50µM. When the 
concentration of insulin analog LVEALYLVC is increased to more than seven times that of 
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hIAPP, it becomes damaging and disrupts the membrane above the levels of hIAPP itself. 
 
 Figure 16. Average percent of dye leakage from model membranes in the presence of varying 
ratios of [LVEALYLVC]: [hIAPP]. 
 
Figure 16 shows percent membrane disruption versus the ratio of inhibitor LVEALYLC 
to hIAPP. It is clear from the graph that insulin analog is reducing membrane disruption at the 
0.2: 1 ratio but is contributing somehow to the membrane damage as the ratio of inhibitor is 
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increased. The liposomes are disrupted to a 15% greater extent at 75µM peptide concentration. 
This result is interesting since the synthesized peptide shows the same approximate ratio range 
for optimal inhibition as does insulin itself (0.2:1 to 2:1), and its reduction in hIAPP induced 
damage (30%) is actually better than that of insulin (15%). However, the increased damage at 
high ratios was not observed with native insulin.  
 
5. SUMMARY 
 Overall, the two synthesized peptides behaved differently at low concentration, with the 
shorter LVEALYLVC demonstrating a similar profile to that of insulin in reducing damage 
caused by hIAPP.  These results are somewhat promising in that truncated analogs may be able 
to mimic the action of insulin in reducing cell damage caused by hIAPP, leading to potential 
peptidomimetic drugs. The longer sequence HLVEALYLVC is not protective at any 
concentration and is in fact an activator of membrane damage. At high concentrations, both 
peptides are destructive, unlike insulin itself. They may actually co-aggregate with hIAPP at high 
concentrations. Given their similar sequences to the internal sequence of hIAPP (ALYLV versus 
ANFLV in hIAPP), they may actually be acting as analogs of hIAPP rather than insulin. 
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6. FUTURE DIRECTIONS 
Future work will include Thioflavin T assays that measure aggregation instead of 
membrane damage so that the cause of the membrane activity can be further elucidated. This will 
provide more information regarding the mechanism of damage and the aggregation process (i.e, 
determine if dye leakage and aggregation/fibril formation are correlated). Eventually more 
peptides will be tested and a shorter and/or more effective insulin analog may be identified. 
Instead of membrane mimicking lipids, the final goal is to do studies in pancreatic cells in-vivo. 
We also want to see if hIAPP competes with insulin and binds at the insulin receptor to impair 
glucose utilization. This may give more insight into understanding how Type II diabetes 
develops.   
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